Sorafenib in liver cancer.

Abstract:

INTRODUCTION:With growing knowledge of the molecular pathway of carcinogenesis, targeted therapies have become the 'blue ocean' of cancer treatment. sorafenib is an oral multikinase inhibitor that targets Raf/mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) (Raf/MEK/ERK) and several tyrosine kinases (VEGFR-2, VEGFR-3, PDGFR-β) that has shown efficacy in hepatocellular carcinoma (HCC). AREAS COVERED:An updated summary of the preclinical and clinical experience with sorafenib in HCC is presented in this paper. Data are based on abstracts from international conferences and journal articles found in a PubMed search of literature published up to December 2011. EXPERT OPINION:Based on favorable data from preclinical and clinical trials, sorafenib has been approved as a standard therapy in advanced HCC. However, further efforts to understand the additional roles of sorafenib in the treatment of HCC are still necessary. Data for sorafenib will guide the development of new drugs for the treatment of HCC.

authors

Woo HY,Heo J

doi

10.1517/14656566.2012.679930

subject

Has Abstract

pub_date

2012-05-01 00:00:00

pages

1059-67

issue

7

eissn

1465-6566

issn

1744-7666

journal_volume

13

pub_type

杂志文章,评审
  • Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.

    abstract:INTRODUCTION:Meropenem-vaborbactam is a new beta-lactam/beta-lactamase inhibitor combination that combines a carbapenem antibiotic with a first-in-class, boronic acid pharmacophore, serine beta-lactamase inhibitor which has potent inhibitory activity against class A carbapenemases, especially Klebsiella pneumoniae carb...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1512586

    authors: Wu G,Cheon E

    更新日期:2018-09-01 00:00:00

  • Long-term oral carvedilol in chronic heart failure.

    abstract::The long-term beta-blockade strategy with carvedilol, metoprolol succinate or bisoprolol is now strongly recommended to reduce the rates of mortality and morbidity in patients with chronic heart failure (CHF). Although the benefits observed with such drugs are viewed as a class effect, theoretically, carvedilol might ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.5.6.1359

    authors: Di Lenarda A,Sabbadini G,Moretti M,Sinagra G

    更新日期:2004-06-01 00:00:00

  • Treatment of adult short bowel syndrome patients with teduglutide.

    abstract:INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.644787

    authors: Nørholk LM,Holst JJ,Jeppesen PB

    更新日期:2012-02-01 00:00:00

  • Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

    abstract:INTRODUCTION:Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier sta...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1496237

    authors: Cretin B

    更新日期:2018-08-01 00:00:00

  • Emerging therapies for ionizing radiation-associated skin field carcinogenesis.

    abstract:BACKGROUND:Radiodermatitis in its acute and chronic presentations represents a set of specific adverse effects resulting from ionizing radiations. Skin-field cancerization is another condition associated to or independent of clinically recognizable radiodermatitis. This condition leads to the risk of later occurrence o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902754060

    authors: Piérard GE,Piérard-Franchimont C,Paquet P,Quatresooz P

    更新日期:2009-04-01 00:00:00

  • Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?

    abstract:INTRODUCTION:For the past three decades, carbapenems played a central role in our antibiotic armamentarium, trusted to effectively treat infections caused by drug-resistant bacteria. The utility of this class of antibiotics has been compromised by the emergence of resistance especially among Enterobacteriaceae. AREAS ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1145658

    authors: Perez F,El Chakhtoura NG,Papp-Wallace KM,Wilson BM,Bonomo RA

    更新日期:2016-01-01 00:00:00

  • Pegaptanib sodium for the treatment of age-related macular degeneration.

    abstract:BACKGROUND:Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeabi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.3.499

    authors: Apte RS

    更新日期:2008-02-01 00:00:00

  • Bendamustine for treatment of chronic lymphocytic leukemia.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) often has an extended disease course. With a median age at diagnosis of 72 years, newer treatment options with less toxicity than standard nucleoside analogue-based regimens are needed. Historically, few therapy options are available once CLL has become refractory to nucl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.693163

    authors: Chang JE,Kahl BS

    更新日期:2012-07-01 00:00:00

  • Summarizing the FIELD study: lessons from a 'negative' trial.

    abstract:INTRODUCTION:Disturbances in lipid metabolism represent an integral component of dysglycemic states and may increase the risk of diabetic complications. Although from a pathophysiological viewpoint fibrates could represent the ideal drug for patients with diabetic dyslipidemia the evidence that support their use in the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.850075

    authors: Tsimihodimos V,Mikhailidis DP,Elisaf M

    更新日期:2013-12-01 00:00:00

  • Pharmacotherapy of helminth infection.

    abstract:BACKGROUND:In the first decade of the 21st century, worm infections are still very common, especially--but not exclusively--in the developing world. OBJECTIVE:To review the current pharmacotherapy of the major trematode, cestode and nematode infections of humans. METHODS:A systematic search of the Cochrane Databank o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902722463

    authors: van den Enden E

    更新日期:2009-02-01 00:00:00

  • Needed, new paradigms in antibiotic development.

    abstract::While antibiotic resistance has grabbed the headlines and the attention of the pharmaceutical industry, the lack of susceptibility of biofilms formed both on animate and inanimate surfaces deserve greater attention from the industry, medical practitioners and regulators. The current literature tells us that the inhere...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656561003724747

    authors: Ceri H,Olson ME,Turner RJ

    更新日期:2010-06-01 00:00:00

  • Flecainide acetate for the treatment of atrial and ventricular arrhythmias.

    abstract:INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.759212

    authors: Apostolakis S,Oeff M,Tebbe U,Fabritz L,Breithardt G,Kirchhof P

    更新日期:2013-02-01 00:00:00

  • A review of olanzapine pamoate.

    abstract:INTRODUCTION:Olanzapine long-acting injection (OLAI), or olanzapine pamoate , is one of three second generation (SGA) antipsychotics now available in a long-acting formulation. OLAI is a microcrystalline salt of pamoic acid and olanzapine suspended in an aqueous solution that slowly dissociates into the separate compon...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2012.686169

    authors: Chue P,Chue J

    更新日期:2012-08-01 00:00:00

  • Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.

    abstract:INTRODUCTION:actinic keratosis is a premalignant disease with a high incidence and is a strong predictor for the development of squamous cell carcinoma. Various treatment options have been established over recent years, including topical treatment with imiquimod, 5-fluorouracil, diclofenac or photodynamic therapy, cryo...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.549128

    authors: Quist SR,Gollnick HP

    更新日期:2011-02-01 00:00:00

  • Phosphate binder usage in kidney failure patients.

    abstract::Phosphorus binders are used in patients with kidney failure because of the incomplete removal of phosphorus with dialysis and the inability to exclude phosphorus from the diet. Aluminium was the initial phosphorus binder used, but was replaced by calcium-containing binders because of the development of aluminium toxic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.6.941

    authors: Bleyer AJ

    更新日期:2003-06-01 00:00:00

  • Treatment of bacterial vaginosis: what we have and what we miss.

    abstract:INTRODUCTION:The disturbing, foul-smelling discharge of bacterial vaginosis (BV) is a nuisance to women. Treatment possibilities for BV are limited and only achieve complete cure in 65 to 85% of cases. In most women, the condition relapses within weeks to months after treatment. AREAS COVERED:In search of new therapeu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.881800

    authors: Donders GG,Zodzika J,Rezeberga D

    更新日期:2014-04-01 00:00:00

  • Pharmacological management of axial spondyloarthritis in adults.

    abstract::Introduction: Spondyloarthritis (SpA) refers to a group of disorders sharing common clinical, genetic and imaging characteristics. Axial (ax) SpA corresponds to a subgroup that mainly affects the axial skeleton, leading to inflammatory back pain and progressive radiographic changes of the sacroiliac joints and the spi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1617853

    authors: Toussirot E

    更新日期:2019-08-01 00:00:00

  • Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

    abstract:INTRODUCTION:Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results. Sorafenib is the first compound to demonstrate a significant effect on survival in HCC...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.546346

    authors: Guan YS,He Q

    更新日期:2011-02-01 00:00:00

  • Evaluation of injection force of three insulin delivery pens.

    abstract:OBJECTIVE:Reduced injection force is among the modifications to the Next Generation FlexPen (NGFP). This force was compared with two other prefilled pens: SoloStar (SS) and KwikPen (KP). RESEARCH DESIGN/METHODS:The injection force of the pens was measured, with either a BD Micro-Fine 31G thin-wall needle, or a NovoFin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560903018929

    authors: Asakura T,Seino H,Kageyama M,Yohkoh N

    更新日期:2009-06-01 00:00:00

  • Management of incomplete remission and treatment resistance in first-episode psychosis.

    abstract:BACKGROUND:Incomplete remission and treatment resistance are common even in first-episode psychosis patients. OBJECTIVE:The aim of this review was to provide an overview of the available interventions and treatment pathways for the management of incomplete remission and treatment resistance in first-episode psychosis....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.12.2039

    authors: Lambert M,Naber D,Huber CG

    更新日期:2008-08-01 00:00:00

  • Nonbiological pharmacotherapies for the treatment of diabetic macular edema.

    abstract:INTRODUCTION:During the past decade, there have been significant advances in the pharmacotherapies for the treatment of diabetic macular edema (DME). Among the presently available treatment options, anti-vascular endothelial growth factors (anti-VEGF) agents are the most favored agents due to their efficacy and safety....

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1100172

    authors: Agarwal A,Parriott J,Demirel S,Argo C,Sepah YJ,Do DV,Nguyen QD

    更新日期:2015-01-01 00:00:00

  • Quality improvement in the management of people with epilepsy and intellectual disability: the development of clinical guidance.

    abstract::Introduction: This clinical guidance looks at the specific concerns of delivery of medical treatment for people with epilepsy and intellectual disability (ID). People with ID have not been included in licensing drug trials of AEDs. However, this population has an over-representation of seizure comorbidity, treatment r...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1695780

    authors: Watkins L,O'Dwyer M,Kerr M,Scheepers M,Courtenay K,Shankar R

    更新日期:2020-02-01 00:00:00

  • Treating myoclonic epilepsy in children: state-of-the-art.

    abstract:INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.800045

    authors: Striano P,Belcastro V

    更新日期:2013-07-01 00:00:00

  • Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.

    abstract:INTRODUCTION:Obesity is a growing health problem that has numerous comorbidities, including cardiovascular disease (CVD). The multi-disciplinary treatment of obesity now includes the use of pharmacotherapy. When treating patients with obesity and CVD, certain medications may be more appropriate than others. AREAS COVE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1561867

    authors: Andrew CA,Saunders KH,Shukla AP,Aronne LJ

    更新日期:2019-04-01 00:00:00

  • New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

    abstract:BACKGROUND:Sitagliptin is a highly selective oral dipeptidyl peptidase-4 inhibitor. This drug increases the plasma concentration of active glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide. These two hormones then simulate the secretion of insulin in a glucose-dependent manner and inhibit glu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.9.1495

    authors: Gagliardino JJ,Santoro S,Arellano S,Di Girolamo G

    更新日期:2008-06-01 00:00:00

  • Pharmacological management of malignant hypertension.

    abstract:INTRODUCTION:According to current guidelines, malignant hypertension is one of the emergencies in hypertension. The definition requires the presence of bilateral retinal hemorrhages or exudates, with or without papilledema, acute heart failure and acute deterioration in renal function in severe hypertension. Patients w...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1732923

    authors: Lewek J,Bielecka-Dąbrowa A,Maciejewski M,Banach M

    更新日期:2020-07-01 00:00:00

  • Evaluating triptorelin as a treatment option for breast cancer.

    abstract::Introduction: Triptorelin is a luteinizing hormone-releasing hormone analog (LH-RHa) inducing ovarian function suppression (OFS). It is approved by FDA and EMA in association with tamoxifen or aromatase inhibitor (AI) and with fulvestrant and palbociclib in premenopausal women with hormone receptor (HR)-positive breas...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2019.1650020

    authors: Ferraro E,Trapani D,Marrucci E,Curigliano G

    更新日期:2019-10-01 00:00:00

  • The management of dermatomyositis: current treatment options.

    abstract::Dermatomyositis is traditionally classified as one of the idiopathic inflammatory myopathies. The traditional approach to the management of patients with dermatomyositis focuses predominantly on end points related to the systemic manifestations of this disorder, especially proximal muscle weakness resulting from myosi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.5.1083

    authors: Sontheimer RD

    更新日期:2004-05-01 00:00:00

  • Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.

    abstract::Clopidogrel has become a mainstay in the management of acute coronary syndrome patients over the past decade, as well as an essential component of percutaneous coronary intervention (PCI) pharmacotherapy. Until recently, no prospective study has evaluated the effectiveness of clopidogrel in the setting of an ST-segmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.12.1669

    authors: Hamdalla H,Moliterno DJ

    更新日期:2006-08-01 00:00:00

  • Itraconazole.

    abstract::Itraconazole is a broad spectrum triazole antifungal agent. It has favourable pharmacodynamic and pharmacokinetic profiles and is available as both oral and i.v. formulations. Over the last two decades, clinical and animal infection studies have demonstrated the efficacy of itraconazole in a wide range of superficial ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.2.287

    authors: Piérard GE,Arrese JE,Piérard-Franchimont C

    更新日期:2000-01-01 00:00:00